At Tolka AI Therapeutics, we are revolutionizing phage therapy with bespoke, personalized cocktails designed to precisely target Mycobacterium abscessus infections. By leveraging patient-specific isolates, we develop GMP-grade phages that are trained and optimized to effectively eliminate the pathogenic strain, offering a tailored therapeutic solution. Our phage formulations are designed for stability at 4°C, ensuring ease of use for patients.
We integrate advanced AI-driven platforms for GMP manufacturing, QA documentation, and cutting-edge processes to remove endotoxins and exotoxins from our phage products. This innovative approach enables us to maintain the highest safety and quality standards while delivering personalized phage therapies in record timelines. With a robust manufacturing pipeline, we are setting new benchmarks in precision medicine to combat antimicrobial resistance and improve patient outcomes.